SG11202005920PA - Compositions comprising lipid-based nanoparticles for treating diabetes mellitus - Google Patents
Compositions comprising lipid-based nanoparticles for treating diabetes mellitusInfo
- Publication number
- SG11202005920PA SG11202005920PA SG11202005920PA SG11202005920PA SG11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA
- Authority
- SG
- Singapore
- Prior art keywords
- lipid
- compositions
- diabetes mellitus
- treating diabetes
- based nanoparticles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862614109P | 2018-01-05 | 2018-01-05 | |
PCT/US2019/012557 WO2019136386A1 (en) | 2018-01-05 | 2019-01-07 | Compositions comprising lipid-based nanoparticles for treating diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005920PA true SG11202005920PA (en) | 2020-07-29 |
Family
ID=67143976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005920PA SG11202005920PA (en) | 2018-01-05 | 2019-01-07 | Compositions comprising lipid-based nanoparticles for treating diabetes mellitus |
Country Status (11)
Country | Link |
---|---|
US (2) | US20200375913A1 (ko) |
EP (1) | EP3735232A4 (ko) |
JP (1) | JP2021509900A (ko) |
KR (1) | KR20200106912A (ko) |
CN (1) | CN111712236A (ko) |
AU (1) | AU2019205795A1 (ko) |
BR (1) | BR112020013460A2 (ko) |
CA (1) | CA3086771A1 (ko) |
MX (1) | MX2020007067A (ko) |
SG (1) | SG11202005920PA (ko) |
WO (1) | WO2019136386A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
US20210137838A1 (en) | 2017-03-13 | 2021-05-13 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
AU2020271901A1 (en) | 2019-04-12 | 2021-11-04 | Sdg, Inc. | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610758A4 (en) * | 2003-03-19 | 2011-11-02 | Harry Hebblewhite | METHOD AND SYSTEM FOR DETERMINING INSULIN DOSAGE PLANES AND CARBOHYDRATE / INSULIN RELATIONSHIPS IN DIABETICS |
WO2004084820A2 (en) * | 2003-03-19 | 2004-10-07 | Harry Hebblewhite | Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
US20110135725A1 (en) * | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
KR101389226B1 (ko) * | 2005-05-23 | 2014-04-25 | 에스디지,인코포레이티드 | 포유동물에게 인슐린을 전달하기 위한 지질 구조물 |
US8962015B2 (en) * | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
US20120035105A1 (en) * | 2009-01-09 | 2012-02-09 | Sdg, Inc. | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments |
EP2683410A2 (en) * | 2011-03-08 | 2014-01-15 | Access Pharmaceuticals, Inc. | Targeted nanocarrier systems for delivery of actives across biological membranes |
US20180000953A1 (en) * | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
US20210137838A1 (en) * | 2017-03-13 | 2021-05-13 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
-
2019
- 2019-01-07 SG SG11202005920PA patent/SG11202005920PA/en unknown
- 2019-01-07 KR KR1020207021607A patent/KR20200106912A/ko not_active Application Discontinuation
- 2019-01-07 MX MX2020007067A patent/MX2020007067A/es unknown
- 2019-01-07 US US16/959,617 patent/US20200375913A1/en not_active Abandoned
- 2019-01-07 JP JP2020537138A patent/JP2021509900A/ja active Pending
- 2019-01-07 BR BR112020013460-0A patent/BR112020013460A2/pt unknown
- 2019-01-07 EP EP19736007.6A patent/EP3735232A4/en active Pending
- 2019-01-07 WO PCT/US2019/012557 patent/WO2019136386A1/en unknown
- 2019-01-07 CA CA3086771A patent/CA3086771A1/en active Pending
- 2019-01-07 CN CN201980013264.1A patent/CN111712236A/zh active Pending
- 2019-01-07 AU AU2019205795A patent/AU2019205795A1/en active Pending
-
2023
- 2023-04-26 US US18/307,459 patent/US20240108585A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240108585A1 (en) | 2024-04-04 |
CN111712236A (zh) | 2020-09-25 |
KR20200106912A (ko) | 2020-09-15 |
BR112020013460A2 (pt) | 2020-12-01 |
US20200375913A1 (en) | 2020-12-03 |
WO2019136386A1 (en) | 2019-07-11 |
MX2020007067A (es) | 2020-09-09 |
CA3086771A1 (en) | 2019-07-11 |
EP3735232A1 (en) | 2020-11-11 |
EP3735232A4 (en) | 2021-09-08 |
JP2021509900A (ja) | 2021-04-08 |
AU2019205795A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253915A1 (zh) | 表面改性用組合物 | |
IL259123B (en) | The compositions for applying to the skin | |
SG11202005920PA (en) | Compositions comprising lipid-based nanoparticles for treating diabetes mellitus | |
GB201715639D0 (en) | Compositions for wound treatment | |
EP3263132A4 (en) | Composition for treating il-6-related diseases | |
HK1258445A1 (zh) | 表面修飾用功能性組合物 | |
EP3252129A4 (en) | Composition for removing sulfur-containing compounds | |
EP3705545A4 (en) | SURFACE TREATMENT COMPOSITION | |
EP3638228C0 (en) | COMPOUNDS FOR TREATING TRIPLE NEGATIVE BREAST CANCER | |
EP3569238A4 (en) | COMPOSITION FOR TREATING NEWBORN EHI | |
EP3609528A4 (en) | COMPOSITIONS FOR THE TREATMENT OF ADDICTION | |
EP3274053A4 (en) | Tolerogenic nanoparticles for treating diabetes mellitus | |
PT3273947T (pt) | Composição para a saúde ocular | |
PL3603686T3 (pl) | Kompozycja wypełniacza do leczenia lipoatrofii | |
EP3288636A4 (en) | COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS | |
EP3555360A4 (en) | COMPOSITION FOR TREATMENT OF FABRICS | |
IL261774B (en) | Compositions for treating dermatological conditions | |
EP3489280A4 (en) | SURFACE TREATMENT AGENT FOR THERMAL CONDUCTING POLYORGANOSILOXANE COMPOSITION | |
SG11202008959RA (en) | Composition for improving skin conditions | |
PT3574912T (pt) | Composição para tratamento de doença diabética | |
EP3632421A4 (en) | COMPOSITION FOR IMPROVING BRAIN FUNCTION | |
EP3369419A4 (en) | Composition for treating diabetes | |
EP3013958A4 (en) | Glucan-encapsulated sirna for treating type 2 diabetes mellitus | |
PL3692130T3 (pl) | Kompozycja obejmująca prekursor składników lotnych | |
ZA201800974B (en) | Combination composition comprising fgf-18 compound |